<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107415">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690663</url>
  </required_header>
  <id_info>
    <org_study_id>815628</org_study_id>
    <nct_id>NCT01690663</nct_id>
  </id_info>
  <brief_title>Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%</brief_title>
  <acronym>Dex Dose</acronym>
  <official_title>Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25% in Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block, a Randomized, Placebo Controlled Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When used in conjunction with a local anesthetic, dexamethasone may prolong both the sensory
      and motor effects of high supraclavicular brachial plexus nerve block (SBP) in arthroscopic
      shoulder surgery. This study seeks to determine if there is a relationship between the
      duration of sensory and motor blockade in supraclavicular brachial plexus nerve blocks (SBP)
      when combined with increasing doses of dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The exact mechanism of dexamethasone on peripheral nerve block is unclear. The current
      theory is that the effect is not dose related, while only 4mg and 8mg doses were studied.
      Our hypothesis is that the dose differences at 1mg, 2mg, or 4mg, does not have significant
      effect on the duration of analgesia. Therefore, we are not considering any patients to
      receive suboptimal dosing of preservative free dexamethasone in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary outcome variable is change in post operative sensory block duration.</measure>
    <time_frame>days 1, 2, and day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is defined as time from the completion of the block to the initiation of supplemental analgesia medications after PACU discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in post operative motor block duration</measure>
    <time_frame>days 1, 2, and day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is defined as time from the completion of the block to the time when patient is able to move his or her forearm and/or hands</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The total post operative opioid consumption from after surgery to 48 hours post operatively.</measure>
    <time_frame>first 48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This time frame includes immediately post operative to the 48-hour time point after surgery.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Post Surgical Pain</condition>
  <arm_group>
    <arm_group_label>Bupivacaine 0.25% mixed with 1ml normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine 0.25% with 1mg dexamethasone (1ml)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine 0.25% mixed with 2mg dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.25%</intervention_name>
    <arm_group_label>Bupivacaine 0.25% mixed with 1ml normal saline</arm_group_label>
    <arm_group_label>Bupivacaine 0.25% with 1mg dexamethasone (1ml)</arm_group_label>
    <arm_group_label>Bupivacaine 0.25% mixed with 2mg dexamethasone</arm_group_label>
    <arm_group_label>Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Bupivacaine 0.25% with 1mg dexamethasone (1ml)</arm_group_label>
    <arm_group_label>Bupivacaine 0.25% mixed with 2mg dexamethasone</arm_group_label>
    <arm_group_label>Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>placebo</description>
    <arm_group_label>Bupivacaine 0.25% mixed with 1ml normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 to 70 scheduled for primary shoulder arthroscopy who have already
             elected to receive and are eligible for regional anesthesia (brachial plexus nerve
             block) prior to consenting for study.

          2. Ability to sign informed consent.

          3. Ability to follow study protocol, and speak, read and write in English.

          4. Must have valid phone number for follow-up purpose.

          5. Must be able to receive all protocol medications to include the dexamethasone,
             ketorolac, hydromorphone, and percocet.

        Exclusion Criteria:

          1. Patient younger than 18 years old and older than age 70

          2. Patient refusal to sign consent

          3. Chronic opioid use (defined as narcotic use longer than 3 months) as documented in
             patient's medical record

          4. Allergy to any of the protocol medications

          5. Patients with severe lung disease, contra lateral phrenic nerve injury,
             insulin-dependent diabetes, hepatic disease/failure, kidney disease/failure as
             documented in patient's medical record

          6. Pregnancy (positive urine pregnancy test result in Preop area on morning of surgery)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiabin Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiabin Liu, MD</last_name>
    <phone>(215) 290-8341</phone>
    <email>jiabin.liu@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary S Hammond, BSN</last_name>
    <phone>215662-3772</phone>
    <email>mary.hammond@uphs.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiabin Liu, MD</last_name>
      <email>jiabin.liu@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary S Hammond, BSN</last_name>
      <email>mary.hammond@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jiabin Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
